Onkologie. 2021:15(6):299-301 | DOI: 10.36290/xon.2021.058

Primary angiosarcoma of the breast

Lenka Svobodová1, 2, Renata Soumarová1, 2
1 Radioterapeutická a onkologická klinika FNKV a 3. lékařské fakulty Univerzity Karlovy, Praha
2 3. lékařská fakulta Univerzity Karlovy, Praha

Primary angiosarcoma of the breast is a rare malignancy, usually affecting young women between the third and fourth decades of life. It is manifested as a palpable, rapidly growing mass in the breast of women with no history of exposure to ionizing radiation. Surgery is the main treatment modality, with the role of radiotherapy and chemotherapy remaining unclear due to a lack of randomized clinical trials. The prognosis of primary angiosarcoma is unfavourable, with a high rate of local recurrence and early haematogenous dissemination, particularly to the lungs, being typical.

Keywords: breast cancer, angiosarcoma, chemotherapy, radiotherapy.

Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svobodová L, Soumarová R. Primary angiosarcoma of the breast. Onkologie. 2021;15(6):299-301. doi: 10.36290/xon.2021.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angiosarcoma. Lancet Oncol. 2010; 11(10): 983-991. Go to original source... Go to PubMed...
    2. Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer. 2003; 97(8): 1832-1840. Go to original source... Go to PubMed...
    3. Zelek L, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21(13): 2583-2588. Go to original source... Go to PubMed...
    4. Hodgson NC, Bowen-Wells C, Moffat F, Franceschi D, Avisar E. Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol. 2007; 30: 570-3. doi: 10.1097/COC.0b013e3181131d62. Go to original source... Go to PubMed...
    5. Mantilla JG, Koenigsberg T, Reig B, et al. Core Biopsy of Vascular Neoplasms of the Breast: Pathologic Features, Imaging, and Clinical Findings. Am J Surg Pathol 2016; 40: 1424-34. Go to original source... Go to PubMed...
    6. Lim SZ, Ong KW, Tan BK, Selvarajan S, Tan PH. Sarcoma of the breast: an update on a rare entity. J Clin Pathol. 2016; 69: 373-381. Go to original source... Go to PubMed...
    7. Gutman H, Pollock RE, Ross MI, et al. Sarcoma of the breast: implications for extent of therapy. Anderson experience. Surgery 1994; 116: 505-9. Go to PubMed...
    8. McGowan TS, Cummings BJ, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys 2000; 46: 383-90. Go to original source... Go to PubMed...
    9. Lahat G, Lev D, et al. Sarcomas of the breast. Expert Rev Anticancer Ther 2012; 12: 1045-51. Go to original source... Go to PubMed...
    10. Gutman H, Pollock RE, Ross Mi, et al. Sarcoma of the breast: implications for extent of therapy. Anderson experience. Surgery 1994; 116: 505-9. Go to PubMed...
    11. Zelek L, Liombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21: 2583-8. Go to original source... Go to PubMed...
    12. Toesca A, Spitaleri G, De Pas T, et al. Sarcoma of the breast: outcome and reconstructive options. Clin Breast Cancer 2012; 12: 438-44. Go to original source... Go to PubMed...
    13. Shet T, Malaviya A, Nadkarni M, et al. Primary angiosarcoma of the breast: observations in Asian Indian women. J Surg Oncol 2006; 94: 368-74. Go to original source... Go to PubMed...
    14. Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol 2010; 11: 983-91. Go to original source... Go to PubMed...
    15. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas Ann Oncol 2013; 24: 257-263. Go to original source... Go to PubMed...
    16. D'Adamo D, Anderson S, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas J Clin Oncol, 2005; 23: 7135-7142. Go to original source... Go to PubMed...
    17. Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: A randomized phase II trial J Clin Oncol 2015; 33: 2797-2802. Go to original source... Go to PubMed...
    18. Italiano A, Chen CL, Thomas R, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: A pattern distinct from other sarcomas with complex genomics Cancer 2012; 118: 5878-5887. Go to original source... Go to PubMed...
    19. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care Oncologist 2005; 10: 833-841. Go to original source... Go to PubMed...
    20. Painter CA, Jain E, Tomson BN, et al. The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 2020; 26: 181-7. Go to original source... Go to PubMed...
    21. Botti G, Scognamiglio G, Marra L, et al. Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma. J Cancer 2017; 8: 3166-72. Go to original source... Go to PubMed...
    22. Wagner MJ, et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021; 9(8): e002990. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.